富祥股份(300497.SZ)證券簡稱擬變更為“富祥藥業”
格隆匯4月10日丨富祥股份(300497.SZ)公佈,2020年4月8日,公司第三屆董事會第十二次會議審議通過了《關於變更公司證券簡稱的議案》,公司將中文證券簡稱由“富祥股份”變更為“富祥藥業”,公司的英文證券簡稱、中文全稱、英文全稱和證券代碼不變。
公司自成立以來不斷健全產品鏈、加強研發優化工藝,發展成為舒巴坦、他唑巴坦,以及培南類藥品的主要原料藥和中間體供應商,是目前業內重要的β-內酰胺酶抑製劑原料藥生產基地,是碳青黴烯類藥物的主要供應商之一,是洛韋類抗病毒藥物中間體的主要供應商之一,產品銷往全球十多個國家和地區,向全球客户提供了優質的產品,得到了國內外諸多知名客户的認可。
公司將繼續發揮自身優勢,致力於“醫藥中間體、原料藥和製劑一體化”,優化資源配置,持續完善主業板塊的產業鏈,使公司業績保持持續穩定增長。隨着醫藥行業政策的不斷調整和行業競爭格局的優化,通過內生式增長和外延式擴展並舉,力爭成為中國知名的製藥企業之一。
為了更加貼合公司產業佈局的實際情況,更準確的反應公司的主營業務性質以及公司未來的發展方向,方便投資者更好理解公司的經營方針、戰略方向和企業的核心競爭力,公司將證券簡稱變更為“富祥藥業”。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.